Welcome to our dedicated page for GSK plc SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK PLC (GLAXF) filings document foreign-issuer disclosures for a global biopharma company registered in England and Wales. The record centers on Form 6-K current reports furnished under the Exchange Act, including announcements on product collaborations, capital-return programs, annual general meeting voting results, remuneration matters, board elections, and transaction notifications involving American Depositary Shares.
The filings also describe GSK's securities framework, including ordinary shares and ADS instruments, share repurchases and treasury-share treatment, PDMR transaction reporting, and governance resolutions connected with annual reporting and shareholder approvals. Product-related reports identify bepirovirsen in chronic hepatitis B and outline regulatory, quality, pharmacovigilance, commercial access, and global medical-strategy responsibilities associated with collaboration arrangements.
GSK announced a five-year, $30 billion investment plan in the United States to expand research, development and supply chain infrastructure. The announcement includes a $1.2 billion package for advanced manufacturing, AI and digital capabilities that will create hundreds of highly skilled U.S. jobs and build a next-generation biologics "flex" factory at Upper Merion, Pennsylvania, with construction planned to begin in 2026. GSK said the wider $30 billion commitment will fund capital projects across its U.S. supply chain, boost R&D drug discovery and clinical trial activity, and increase the U.S. share of its global clinical studies. The filing notes GSK has added roughly $2 billion in U.S. manufacturing investments over the last 12 months, including an $800 million Marietta, Pennsylvania facility started in October 2024, and that its global supply chain delivered 1.7 billion packs of medicines and over 400 million vaccine doses last year.
GSK plc announced that, acting through Merrill Lynch International, it repurchased 210,377 ordinary shares on 16 September 2025 at prices between 1,462.00p and 1,478.00p per share, with an aggregated average shown as 1,468.98p. These shares will be held as treasury stock as part of the buyback programme announced 4 June 2025. Since 4 June 2025 the company has repurchased 29,104,717 ordinary shares. After this trade GSK holds 247,239,100 shares in treasury and has 4,068,163,868 ordinary shares in issue (excluding treasury), giving total voting rights of 4,068,163,868 and treasury-held voting rights of 6.08%.
GSK plc reported a purchase of ordinary shares under its ongoing buyback programme. On 15 September 2025 the Company, acting through Merrill Lynch International, purchased 253,331 ordinary shares at prices ranging up to 1,505.50p, with an aggregated weighted lowest/highest/average price line reported as 1,476.00p / 1,505.50p / 1,482.92p on that date. Since the non-discretionary agreement with the Broker dated 4 June 2025, GSK has purchased 28,894,340 ordinary shares in total. Following the 15 September purchase the Company holds 247,028,723 shares in treasury and has 4,068,374,245 ordinary shares in issue (excluding treasury), giving total voting rights of 4,068,374,245 and treasury shares representing 6.07% of voting rights.